Articles Mentioning Pharmaceuticals Stocks

Results 1 - 10 of 927 : 1 2 3 4 5 6 7 8 9 Next

Get RSS Feed for Pharmaceuticals

Investing | July 28, 2015

Are These 2 Big Pharmas Really Buyout Candidates?

AstraZeneca and Bristol-Myers Squibb's names have both repeatedly surfaced on the buyout rumor mill this year. Do these rumors have legs, or are they nothing more than speculation?

Investing | June 29, 2015

Better Dividend Stock: AbbVie or Johnson & Johnson?

AbbVie and Johnson & Johnson are widely recognized as top-tier dividend stocks. Here is a look at which one offers the better long-term prospects for income-seeking investors.

Investing | June 27, 2015

The Johnson & Johnson Numbers You Should Know

Let's take advantage of the calm before the earnings storm to put together your earnings checklist.

Investing | June 11, 2015

3 Things AbbVie Inc.'s Management Wants You to Know

AbbVie's management team had a lot to talk about on their last investor conference call. Here are my three takeaways you need to know when considering the stock for investment.

Investing | June 10, 2015

Cancer Stocks: 2 to Sell, 1 to Buy

Advaxis, Ariad Pharmaceuticals, and Exelixis Inc. are three cancer fight companies that could generate out-sized gains for investors. A deeper look, however, suggests that only one company is a compelling buy right now.

Investing | June 10, 2015

Cancer Stocks: 2 to Sell, 1 to Buy

Advaxis, Ariad Pharmaceuticals, and Exelixis Inc. are three cancer fight companies that could generate out-sized gains for investors. A deeper look, however, suggests that only one company is a compelling buy right now.

Investing | June 07, 2015

Cancer Drugs: 2 Stocks to Watch

AstraZeneca and Agenus Inc. are paving the way for a new generation of breakthrough cancer drugs that boost the immune system's ability to detect and eradicate malignancies. Here's what investors need to know about these two biopharmas going forward.

Investing | May 31, 2015

Why AbbVie, Inc. Is a Better Long-Term Buy Than Gilead Sciences, Inc.

AbbVie and Gilead are often compared because of their competing hepatitis C drugs. These two biopharmas nevertheless have fundamentally different core areas of expertise and approaches to drug development. And these differences give AbbVie a better long-term outlook than Gilead.

Investing | May 30, 2015

Amgen Inc: Why You Shouldn't Count Chickens Before They Hatch

Amgen has shelved its once-promising psoriasis drug. Should investors worry?

Investing | May 17, 2015

Is Gilead Sciences Its Own Worst Enemy?

Gilead Sciences has an amazing track record of bringing game-changing new drugs to market. Could this unique ability also be the company's biggest weakness?

Results 1 - 10 of 927 : 1 2 3 4 5 6 7 8 9 Next

Get RSS Feed for Pharmaceuticals